Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Genetic testing and PARP inhibitors in metastatic prostate cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.06.19
Views: 2097
Rating:

Dr Neal Shore and Dr Joaquin Mateo

Dr Neal Shore (Carolina Urologic Research Center, South Carolina, USA) and Dr Joaquin Mateo (Vall d'Hebron Institute of Oncology, Barcelona, Spain) provide an overview on the history and mechanisms of action of PARP inhibitors. They discuss the relevance of defects within the DNA damage repair (DDR) pathway and introduce the concept of PARP inhibitors for treatment of prostate cancer.

The experts go on to summarise the difference between germline and somatic mutations and provide insights into the difficulties and considerations when testing for these mutations.

Dr Shore and Dr Mateo reflect on the importance of genetic testing for families and for the selection of treatment for patients. They address the need for comprehensive genetic profiling to detect future mutations and conclude by offering advice to clinicians on how to obtain samples and what is required from the clinical community who treat patients with prostate cancer.

PARP inhibitors and their mechanism of action in breast and ovarian cancers
Utilising PARP inhibitors for the treatment of prostate cancer
Considerations and challenges for identifying somatic and germline mutations
Clinical paradigms for genetic testing
Future prospects and recommendations for clinicians

This programme has been supported by an unrestricted educational grant from AstraZeneca.

Categories:

· ASCO 2019

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation